View Rule
View EO 12866 Meetings | Printer-Friendly Version Download RIN Data in XML |
HHS/FDA | RIN: 0910-AH61 | Publication ID: Fall 2017 |
Title: ●Current Good Manufacturing Practice for Outsourcing Facilities | |
Abstract:
This rule would set forth the minimum current good manufacturing practice (cGMP) requirements for human drug products compounded by an outsourcing facility. |
|
Agency: Department of Health and Human Services(HHS) | Priority: Economically Significant |
RIN Status: First time published in the Unified Agenda | Agenda Stage of Rulemaking: Proposed Rule Stage |
Major: Undetermined | Unfunded Mandates: Undetermined |
EO 13771 Designation: Regulatory | |
CFR Citation: 21 CFR 212 | |
Legal Authority: 21 U.S.C. 351 21 U.S.C. 371 |
Legal Deadline:
None |
||||||
Timetable:
|
Regulatory Flexibility Analysis Required: Undetermined | Government Levels Affected: Undetermined |
Small Entities Affected: No | Federalism: Undetermined |
Included in the Regulatory Plan: No | |
RIN Data Printed in the FR: No | |
Agency Contact: Ashley Boam Health Science Administrator Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research, Building 51, Room 4192, 10903 New Hampshire Avenue, Silver Spring, MD 20993 Phone:301 796-6341 Email: ashley.boam@fda.hhs.gov |